Stock Events

Stock Events

KalVista Pharmaceuticals 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4XC1.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetically defined diseases, competing in the same rare disease space as KalVista.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in creating small molecule drugs for serious diseases, directly competing with KalVista's approach in drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious diseases, including therapies that could compete with KalVista's portfolio.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, competing for similar patient populations as KalVista.
AMGEN
AMGN
Mkt Cap187.56B
Amgen develops therapeutics in areas including cardiovascular disease, competing with KalVista's efforts in hereditary angioedema.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a broad range of healthcare products including innovative medicines, directly competing across multiple areas including treatments for diseases targeted by KalVista.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences focuses on antiviral drugs for infectious diseases, but its expansion into other therapeutic areas could position it as a competitor to KalVista.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie works on a broad portfolio of drugs, including efforts in immunology and oncology, areas that could intersect with KalVista's therapeutic targets.

About

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Show more...
CEO
Mr. Benjamin L. Palleiko
Employees
275
Country
Germany
ISIN
US4834971032

Listings

MU
DE
4XC1.MU
STU
DE
4XC1.STU
F
DE
4XC1.F
XNAS
US
KALV

0 Comments

Share your thoughts

FAQ

What is KalVista Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange KalVista Pharmaceuticals stocks are traded under the ticker 4XC1.MU.
How many employees does KalVista Pharmaceuticals have?▼
As of April 11, 2026, the company has 275 employees.
In which sector is KalVista Pharmaceuticals located?▼
KalVista Pharmaceuticals operates in the Health & Wellness sector.
When did KalVista Pharmaceuticals complete a stock split?▼
KalVista Pharmaceuticals has not had any recent stock splits.
Where is KalVista Pharmaceuticals headquartered?▼
KalVista Pharmaceuticals is headquartered in Framingham, Germany.